MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 540219 | Name: Ikarugamycin

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ikarugamycin is a protein translation inhibitor. It also inhibits CCP-dependent phagocytosis and inhibits uptake of oxidized LDL in macrophages.

Chemical Structure

Ikarugamycin
Ikarugamycin
CAS#36531-78-9

Theoretical Analysis

MedKoo Cat#: 540219

Name: Ikarugamycin

CAS#: 36531-78-9

Chemical Formula: C29H38N2O4

Exact Mass: 478.2832

Molecular Weight: 478.63

Elemental Analysis: C, 72.77; H, 8.00; N, 5.85; O, 13.37

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
IUPAC/Chemical Name
N/A
InChi Key
WSUGGLXIPUHOSG-OKURCWDDSA-N
InChi Code
InChI=1S/C29H38N2O4/c1-3-18-16(2)14-22-20(18)10-11-21-19-6-4-8-26(33)30-13-5-7-24-28(34)27(29(35)31-24)25(32)12-9-17(19)15-23(21)22/h4,8-12,16-24,34H,3,5-7,13-15H2,1-2H3,(H,30,33)(H,31,35)/b8-4+,12-9+/t16-,17+,18-,19+,20-,21+,22-,23+,24+/m0/s1
SMILES Code
CC[C@H]1[C@@H](C)C[C@H]2[C@H]1C=C[C@H]3[C@H]2C[C@@H](/C=C/4)[C@H]3C/C=C/C(NCCC[C@@H](NC5=O)C(O)=C5C4=O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 478.63 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Antosch J, Schaefers F, Gulder TA. Heterologous reconstitution of ikarugamycin biosynthesis in E. coli. Angew Chem Int Ed Engl. 2014 Mar 10;53(11):3011-4. doi: 10.1002/anie.201310641. Epub 2014 Feb 12. PubMed PMID: 24519911. 2: Lacret R, Oves-Costales D, Gómez C, Díaz C, de la Cruz M, Pérez-Victoria I, Vicente F, Genilloud O, Reyes F. New ikarugamycin derivatives with antifungal and antibacterial properties from Streptomyces zhaozhouensis. Mar Drugs. 2014 Dec 29;13(1):128-40. doi: 10.3390/md13010128. PubMed PMID: 25551780; PubMed Central PMCID: PMC4306928. 3: Elkin SR, Oswald NW, Reed DK, Mettlen M, MacMillan JB, Schmid SL. Ikarugamycin: A Natural Product Inhibitor of Clathrin-Mediated Endocytosis. Traffic. 2016 Oct;17(10):1139-49. doi: 10.1111/tra.12425. Epub 2016 Aug 8. PubMed PMID: 27392092; PubMed Central PMCID: PMC5260662. 4: Zhang G, Zhang W, Zhang Q, Shi T, Ma L, Zhu Y, Li S, Zhang H, Zhao YL, Shi R, Zhang C. Mechanistic insights into polycycle formation by reductive cyclization in ikarugamycin biosynthesis. Angew Chem Int Ed Engl. 2014 May 5;53(19):4840-4. doi: 10.1002/anie.201402078. Epub 2014 Apr 6. PubMed PMID: 24706593. 5: Greunke C, Antosch J, Gulder TA. Promiscuous hydroxylases for the functionalization of polycyclic tetramate macrolactams--conversion of ikarugamycin to butremycin. Chem Commun (Camb). 2015 Mar 28;51(25):5334-6. doi: 10.1039/c5cc00843c. PubMed PMID: 25711294. 6: Liu C, Wang X, Zhao J, Liu Q, Wang L, Guan X, He H, Xiang W. Streptomyces harbinensis sp. nov., an endophytic, ikarugamycin-producing actinomycete isolated from soybean root [Glycine max (L.) Merr]. Int J Syst Evol Microbiol. 2013 Oct;63(Pt 10):3579-84. doi: 10.1099/ijs.0.050088-0. Epub 2013 Apr 12. PubMed PMID: 23584286. 7: Kyeremeh K, Acquah KS, Sazak A, Houssen W, Tabudravu J, Deng H, Jaspars M. Butremycin, the 3-hydroxyl derivative of ikarugamycin and a protonated aromatic tautomer of 5'-methylthioinosine from a Ghanaian Micromonospora sp. K310. Mar Drugs. 2014 Feb 14;12(2):999-1012. doi: 10.3390/md12020999. PubMed PMID: 24534843; PubMed Central PMCID: PMC3944527. 8: Hasumi K, Shinohara C, Naganuma S, Endo A. Inhibition of the uptake of oxidized low-density lipoprotein in macrophage J774 by the antibiotic ikarugamycin. Eur J Biochem. 1992 Apr 15;205(2):841-6. PubMed PMID: 1572375. 9: Popescu R, Heiss EH, Ferk F, Peschel A, Knasmueller S, Dirsch VM, Krupitza G, Kopp B. Ikarugamycin induces DNA damage, intracellular calcium increase, p38 MAP kinase activation and apoptosis in HL-60 human promyelocytic leukemia cells. Mutat Res. 2011 May 10;709-710:60-6. doi: 10.1016/j.mrfmmm.2011.03.001. Epub 2011 Mar 12. PubMed PMID: 21392513. 10: Xu MJ, Wang JH, Bu XL, Yu HL, Li P, Ou HY, He Y, Xu FD, Hu XY, Zhu XM, Ao P, Xu J. Deciphering the streamlined genome of Streptomyces xiamenensis 318 as the producer of the anti-fibrotic drug candidate xiamenmycin. Sci Rep. 2016 Jan 8;6:18977. doi: 10.1038/srep18977. PubMed PMID: 26744183; PubMed Central PMCID: PMC4705527. 11: Zhang G, Zhang W, Saha S, Zhang C. Recent Advances in Discovery, Biosynthesis and Genome Mining of Medicinally Relevant Polycyclic Tetramate Macrolactams. Curr Top Med Chem. 2016;16(15):1727-39. Review. PubMed PMID: 26456464. 12: Luo T, Fredericksen BL, Hasumi K, Endo A, Garcia JV. Human immunodeficiency virus type 1 Nef-induced CD4 cell surface downregulation is inhibited by ikarugamycin. J Virol. 2001 Mar;75(5):2488-92. PubMed PMID: 11160755; PubMed Central PMCID: PMC114835. 13: Jomon K, Kuroda Y, Ajisaka M, Sakai H. A new antibiotic, ikarugamycin. J Antibiot (Tokyo). 1972 May;25(5):271-80. PubMed PMID: 4625358. 14: Bandmann V, Homann U. Clathrin-independent endocytosis contributes to uptake of glucose into BY-2 protoplasts. Plant J. 2012 May;70(4):578-84. doi: 10.1111/j.1365-313X.2011.04892.x. Epub 2012 Feb 16. PubMed PMID: 22211449. 15: Malcomson B, Wilson H, Veglia E, Thillaiyampalam G, Barsden R, Donegan S, El Banna A, Elborn JS, Ennis M, Kelly C, Zhang SD, Schock BC. Connectivity mapping (ssCMap) to predict A20-inducing drugs and their antiinflammatory action in cystic fibrosis. Proc Natl Acad Sci U S A. 2016 Jun 28;113(26):E3725-34. doi: 10.1073/pnas.1520289113. Epub 2016 Jun 10. PubMed PMID: 27286825; PubMed Central PMCID: PMC4932930. 16: Greunke C, Glöckle A, Antosch J, Gulder TA. Biocatalytic Total Synthesis of Ikarugamycin. Angew Chem Int Ed Engl. 2017 Apr 3;56(15):4351-4355. doi: 10.1002/anie.201611063. Epub 2017 Jan 27. PubMed PMID: 28128495. 17: Huang EW, Liu CZ, Liang SJ, Zhang Z, Lv XF, Liu J, Zhou JG, Tang YB, Guan YY. Endophilin-A2-mediated increase in scavenger receptor expression contributes to macrophage-derived foam cell formation. Atherosclerosis. 2016 Nov;254:133-141. doi: 10.1016/j.atherosclerosis.2016.10.009. Epub 2016 Oct 6. PubMed PMID: 27741419. 18: Li H, Ye X, Guo X, Geng Z, Wang G. Effects of surface ligands on the uptake and transport of gold nanoparticles in rice and tomato. J Hazard Mater. 2016 Aug 15;314:188-96. doi: 10.1016/j.jhazmat.2016.04.043. Epub 2016 Apr 19. PubMed PMID: 27131459. 19: Onelli E, Prescianotto-Baschong C, Caccianiga M, Moscatelli A. Clathrin-dependent and independent endocytic pathways in tobacco protoplasts revealed by labelling with charged nanogold. J Exp Bot. 2008;59(11):3051-68. doi: 10.1093/jxb/ern154. Epub 2008 Jul 4. PubMed PMID: 18603619; PubMed Central PMCID: PMC2504345. 20: Bandmann V, Müller JD, Köhler T, Homann U. Uptake of fluorescent nano beads into BY2-cells involves clathrin-dependent and clathrin-independent endocytosis. FEBS Lett. 2012 Oct 19;586(20):3626-32. doi: 10.1016/j.febslet.2012.08.008. Epub 2012 Aug 27. PubMed PMID: 23046971.